We have also demonstrated that IGFBP-3 exhibits potent IGF-independent antiangiogenic activities in non-small cell lung cancer (NSCLC) cells, HNSCC cells, and HUVECs in vitro and in vivo [6, 8, 9]. This evidence concerns the gene IGF1 and non-small cell lung carcinoma.